Search Results

You are looking at 1 - 10 of 53 items for

  • Author: A. VON ZUR MÜHLEN x
Clear All Modify Search
Restricted access

S. Zabransky, A. von zur Mühlen and ]. Köbberling

ABSTRACT

d-Triiodothyronine (d-T3) is used in the treatment of hyperlipidaemia. To examine the influence of this kind of therapy on thyroid function the effect of various doses of d-T3 on TRH induced TSH release has been studied in 10 male euthyroid subjects. d-T3 was administered orally for 4 days; blood samples were taken on the first day 12 h after the d-T3 dose and then after an additional 12 h and after 4 days. The final sample was taken on the 5th day after 24 h without d-T3. Administration of 31.25 μg of d-T3 reduced the maximum increase of TSH in response to 200 μg TRH iv by 40%; 62.5 and 125 μg of d-T3 did not produce a significantly higher inhibition (50%; 45%). However, after 250 μg of d-T3, the response to a single dose was reduced by 68 %. After 500 μg of d-T3 TRH did not stimulate TSH at all. After 4 days regardless of d-T3 dosage the inhibition was not significantly lower than after 24 h. Prolonging the administration of 500 μg d-T3 over 3 weeks raised PBI to 150% whereas thyroxine fell to 65% of the values before d-T3 administration. In a primary hypothyroid patient the basal TSH secretion was lowered from 63 to 36 μU/ml by a daily dose of 0.5 mg d-T3 for 12 days. This study demonstrates that TSH release is inhibited by small doses of d-T3. This stresses the importance of assessing thyroid function in patients receiving d-T3.

Restricted access

C. R. Pickardt and A. von zur Mühlen

Restricted access

K.-D. Döhler, A. von zur Mühlen and U. Döhler

ABSTRACT

Pituitary content and concentration of LH, FSH and prolactin were measured by radioimmunoassay (RIA) at 2-day intervals from birth to puberty in female and male rats. During the first 2 to 3 weeks of life all hormones were low in pituitary content and concentration in both sexes. They all increased in females during the third and fourth week, but decreased sharply during the days before vaginal opening. During the first ovulatory cycle pituitary content and concentration of LH and prolactin increased again, FSH, however, remained low. In males, pituitary LH, FSH and prolactin content reached peak levels during puberty. Our results show a distinct sexual dimorphism for pituitary FSH. Pituitary LH and prolactin content and concentration patterns show similar tendencies in both sexes with a delay of several days in males. The dramatic changes in female pituitary hormone concentrations just before the first ovulation were not detected in males before the first occurrence of mature spermatozoa in the tubuli of the testes.

Restricted access

G. BRABANT, K. OCRAN, U. RANFT and A. VON ZUR MÜHLEN

Restricted access

C. JAKOBI, ST. NIESSERT, K. BEHRENS and A. VON ZUR MÜHLEN

Free access

B Mayr, G Brabant and A von zur Muhlen

Serum calcitonin screening has recently been found to be a useful supplement to fine-needle aspiration biopsy, ultrasound and radionuclide imaging in the evaluation of thyroid nodules. We describe a case where introduction of routine calcitonin screening in nodular thyroid disease led to the detection of a family with medullary thyroid carcinoma. The benefits and problems of basal and stimulated serum calcitonin testing and ret-proto-oncogene mutation studies are exemplified and we discuss the appropriate use and interpretation of these tests. We conclude that routine basal serum calcitonin measurement in nodular thyroid disease and thoughtful use of ret-mutation analysis is cost-effective in detecting medullary thyroid carcinoma and multiple endocrine neoplasia type II.